Ideas are copied quickly and general purpose technologies or insights in one field can be applied in others.
Month: February 2021
Plus adds $200m in funding
Wanxiang International Investment co-led a round for the automated trucking system developer that included existing backer Full Truck Alliance.
Day One progresses to $130m series B
Access Biotechnology returned for a round that will push Day One Biopharmaceuticals’ paediatric drug candidate through a phase 2 study.
RapidSOS rescues $85m in series C round
The AAA, CSAA, Microsoft and Motorola Solutions-backed emergency response software developer’s latest round, led by Insight Partners, brought its total funding to $200m.
Armis arms itself with $125m
CapitalG took part in a round that valued the cybersecurity software provider at $2bn and came just over a year after it was acquired for $1.1bn.
PGDx picks up $103m in series C
The round brought the total raised by the oncology diagnostics technology developer, backed by Bristol Myers Squibb, Helsinn and Inova Health, to $244m.
Notch marks $85m series A round
Existing strategic investor Allogene Therapeutics has taken part in an $85m series A round for Notch Therapeutics, which is working on cancer treatments.
Drug Farm harvests $56m
The WuXi AppTec-backed round will help the hepatitis B drug developer begin human trials for its lead drug candidate.
SentinelOne tips Scalyr to $155m acquisition
Bloomberg Beta and GV are set to exit the data analytics technology developer in a $155m transaction that will follow about $33m in funding.
Jüsto stacks $65m for series A
The Bimbo and Femsa-backed online grocer has now received over $100m in total, having raised $65m from venture capital investors for its series A round.
SpyBiotech detects GV for series A round
GV returned for SpyBiotech’s $32.5m series A round, as it looks to move its first potential vaccine into the clinic by early next year.
TransThera Biosciences takes in $50m
China Merchants Group participated in a series C-plus round for the cancer and inflammatory disease drug developer.
Evolve BioSystems revolves to series D
The probiotics developer secured an undisclosed amount as Cargill co-led the first close of a series D round with a $55m target.
IST Cube squares $48m fund
Vienna Insurance is among the limited partners for a $48m seed-stage fund aimed at university spinouts in Austria.